The OS win from HARMONi-2 de-risks ivonescimab's overall survival profile ahead of the November 14 PDUFA date for HARMONi. Traders should watch for presentation of the HARMONi-2 OS data at an upcoming medical conference and any FDA feedback on the BLA. Near-term upside hinges on FDA acceptance and label breadth for HARMONi, plus enrollment updates in HARMONi-7.
Price Chart
Executive Summary
Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembrolizumab in the Phase III HARMONi-2 study (PD-L1-positive advanced NSCLC, China). HARMONi-2 already met its primary PFS endpoint (HR 0.51, p<0.0001) and received NMPA approval in China in April 2025. The OS win adds to ivonescimab's favorable risk/reward profile ahead of Summit's November 14, 2026 PDUFA date for HARMONi (EGFR-mutated NSCLC), while Summit's own HARMONi-7 global monotherapy study in PD-L1-high NSCLC is enrolling. This cross-filing positive readout supports Summit's ivonescimab franchise but remains a single-region China study — the pivotal confirmatory data for US/Europe approval will come from Summit's HARMONi trial.
Key Facts
- Phase III HARMONi-2 showed statistically significant OS benefit for ivonescimab vs pembrolizumab monotherapy in PD-L1-positive advanced NSCLC
- HARMONi-2 is a single-region China study by partner Akeso — data exclusively generated, managed, and analyzed by Akeso
- Ivonescimab already approved by China's NMPA (April 2025) based on the primary PFS endpoint (HR 0.51, 95% CI 0.38-0.69, p<0.0001)
- Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi) was accepted by FDA in January 2026; PDUFA date is November 14, 2026
- Summit is enrolling HARMONi-7 (global Phase III, ivonescimab monotherapy vs pembrolizumab in PD-L1-high 1L NSCLC)
- Five Phase III ivonescimab trials have read out positive to date, all five with positive data
- No financial data (revenue, EPS, margins) was included in this filing
Financial Impact
No revenue or financial data reported; positive OS readout from partner study reduces regulatory risk for Summit's ivonescimab program and may improve commercial probability of success
Risk Factors
- HARMONi-2 is a single-region China study; results may not fully replicate in multinational pivotal trials
- Ivonescimab is not yet approved in Summit's license territories (US, Europe)
- No financial data filed — assessment relies on clinical trial trajectory, not reported revenue or profits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000076 |
| Document: a2026_prx0902xharmoni-2o.htm | 0001599298-26-000076 |
| Document: 0001599298-26-000076-index-headers.html | 0001599298-26-000076 |
| Document: 0001599298-26-000076-index.html | 0001599298-26-000076 |
| Document: 0001599298-26-000076.txt | 0001599298-26-000076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access